Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Phase 1
20
about 4.3 years
18+
1 site in OR
What this study is about
This trial is testing a treatment with venetoclax, dasatinib, prednisone, rituximab, and blinatumomab in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is newly diagnosed or has returned. The goal is to determine if this combination can effectively treat these types of leukemia.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Blinatumomab
- 2.Receive Rituximab
- 3.Take Dasatinib
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
blinatumomab, dasatinib, methotrexate, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), venetoclax
injection, intravenous, oral (Oral Tablet), oral, infusion
Primary: Incidence of adverse events, Incidence of dose-limiting toxicities
Secondary: Overall survival, Progression-free survival
biopsy, diagnostic
Oncology